You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 8,992,907

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,992,907

Title:	Compositions for treating an intestinal inflammatory condition
Abstract:	Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition.
Inventor(s):	Foussat; Arnaud (Biot, FR)
Assignee:	Txcell (Valbonne, FR)
Application Number:	12/744,697
Patent Claims:	1. A method for treating an intestinal inflammatory condition in a human subject in need thereof, consisting of administering to the subject an effective amount of a composition consisting of at least one human Tr1 cell population directed against a food antigen from common human diet. 2. The method according to claim 1, wherein said intestinal inflammatory condition is an inflammatory bowel disease. 3. The method according to claim 2, wherein said inflammatory bowel disease is Crohn's disease. 4. The method according to claim 2, wherein said inflammatory bowel disease is ulcerative colitis. 5. The method according to claim 1, wherein said intestinal inflammatory condition is an intestinal inflammation linked to food allergy or intolerance. 6. The method according to claim 5, wherein said intestinal inflammation is linked to milk protein allergy. 7. The method according to claim 5, wherein said intestinal inflammation is linked to celiac disease. 8. The method according to claim 5, wherein said intestinal inflammation is linked to hen egg allergy. 9. The method according to claim 5, wherein said intestinal inflammation is linked to peanut allergy. 10. The method according to claim 1, wherein the composition comprises human Tr1 cells autologous to the cells of said subject. 11. The method according to claim 1, wherein 10.sup.4/kg to 10.sup.9/kg Tr1 cells are administered to the subject in need thereof. 12. A method for treating an intestinal inflammatory condition in a human subject in need thereof, consisting of administering to the subject an effective amount of a composition consisting of at least one human Tr1 cell population directed against a food antigen from common human diet, and one or more therapeutic agents used for treating an intestinal inflammatory condition. 13. The method according to claim 1, wherein said subject has not responded adequately to one or more therapeutic agents selected from the group consisting of: anti-TNF antibody, natalizumab, anti-IL-1 antibody, anti-IL-6 antibody, anti-IL-12 antibody, anti-IL-17 antibody, anti-IL-23 antibody, IL-1 receptor antagonist analogs, aminosalicyclic acid and analogs, corticoids, probiotics, methotrexate, azathioprine, 6-mercaptopurine, thalidomide, and leflunomide. 14. A process for treating an intestinal inflammatory condition in a human subject in need thereof, comprising: obtaining human Tr1 cells directed to a selected food antigen from common human diet, said human Tr1 cells being obtained from a blood sample of said subject, cloning said human Tr1 cells directed to a selected food antigen from common human diet, further expanding said cloned human Tr1 cells obtained at the previous step, and performing the method of claim 1 on the subject. 15. The process according to claim 14, wherein the human Tr1 clones are administered to the subject by an intravenous route. 16. A method for treating an intestinal inflammatory condition in a human subject in need thereof, consisting of administering to the subject an effective amount of a composition comprising at least one human Tr1 cell population directed against a food antigen from common human diet, wherein the composition is administered to the subject not together with or in combination with the food antigen from common human diet. 17. The method according to claim 1, wherein the composition consisting of the at least one human Tr1 cell population is administered to the subject by an intravenous route. 18. The method according to claim 1, wherein the human subject in need thereof suffers from a chronic intestinal inflammatory condition. 19. The method according to claim 1, wherein the human subject in need thereof suffers from a pre-existing intestinal inflammatory condition. 20. The method according to claim 1, wherein said food antigen from common human diet is selected from the group consisting of: ovalbumin, casein, beta-lactoglobulin, soya protein, gliadin, peanuts, and fragments, and mixtures thereof.

Details for Patent 8,992,907

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004	⤷ Try a Trial	2027-11-26
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder	Powder	125696	01/31/2020	⤷ Try a Trial	2027-11-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.